• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Affirm + FuturHealth Partner to Make GLP-1 Medications More Accessible with Flexible Payment Options

by Jasmine Pennic 03/25/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– FuturHealth, a provider of personalized weight-loss solutions partners with Affirm, the payment network that empowers consumers and helps merchants drive growth. 

– The collaboration will enable FuturHealth customers to use Affirm’s flexible, transparent pay-over-time options to purchase medications and wellness solutions.

Flexible, Transparent Way to Pay Over Time for GLP-1 Medications and Wellness Solutions

Now, FuturHealth customers who are approved can finance the purchase of various weight-loss medications, including branded GLP-1 options such as Wegovy and Ozempic, as well as personalized meal plans, consultations, and lab services.

These medications and wellness solutions have proven effective in managing weight and related health conditions but often come with a significant cost, sometimes exceeding $1000 per month. By integrating Affirm, FuturHealth aims to provide a more accessible and responsible way for customers to afford these important treatments and services.

How it Works

Applying for Affirm is straightforward. During checkout on FuturHealth’s website, customers can select Affirm as their preferred payment method. They will then undergo a quick eligibility check. If approved, customers can choose from customized biweekly or monthly payment plans, with interest rates as low as 0% APR, and confirm their purchase.

Affirm adheres to responsible lending practices, ensuring that customers are only approved for financing that Affirm believes they can repay. Furthermore, Affirm does not charge any late or hidden fees, providing customers with a transparent and predictable payment experience.

Availability

Customers can now visit FuturHealth’s website and select Affirm as a payment option when purchasing their weight-loss medications and services. This partnership aims to make effective weight management more accessible and affordable, empowering individuals to take control of their health journey.

“Launching with Affirm is an important step in advancing FuturHealth’s mission to make personalized, science-backed wellness more accessible at scale,” said FuturHealth co-founder & CEO Luke Mahoney. “Flexible, transparent payment options are essential to that goal, and Affirm’s breadth of payment plans — including longer terms — and commitment to no late or hidden fees were key reasons we chose to offer them at checkout. This launch helps us deliver high-quality care with greater convenience for our customers.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: GLP-1

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |